文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

波哥大引入孕妇普遍接种Tdap后婴儿百日咳发病率与死亡率变化

Incidence and mortality of pertussis disease in infants <12 months of age following introduction of pertussis maternal universal mass vaccination in Bogotá, Colombia.
PubMed 文献 · Vaccine · 2020-10-02

该研究基于哥伦比亚波哥大SIVIGILA监测数据,比较孕妇Tdap普遍接种前(2005-2012)与后(2014-2016)<12月龄婴儿百日咳发病与死亡趋势。结果显示接种后<12月龄婴儿发病率由209.4/10万降至49.1/10万(下降87.5%,95%CI 77.2-93.2%),死亡减少100%,2014-2016年无百日咳死亡报告,提示孕妇免疫可能有助于降低婴儿百日咳负担。

要点

  • 孕妇Tdap接种后<12月龄婴儿百日咳发病率下降87.5%(95%CI 77.2-93.2%)。
  • ≤6周龄婴儿发病率下降54.4%(95%CI 35.4-67.9%),降幅小于较大婴儿。
  • 2014-2016年<12月龄婴儿无百日咳死亡报告,死亡率下降100%。

核心结论

  • 波哥大实施孕妇Tdap免疫可能促使<12月龄婴儿百日咳发病率与死亡率下降。

研究设计与样本

  • 基于SIVIGILA监测数据的趋势分析,收集2005-2016年<12月龄婴儿百日咳病例与死亡,比较2005-2012年与2014-2016年两个时期。
  • 分析按<12月龄及≤6周、7-<28周、28-52周三年龄组比较发病率,死亡比较覆盖全部<12月龄婴儿。

主要发现

  • 2005-2016年<12月龄婴儿报告2315例实验室或临床确诊百日咳病例,其中≤6周龄278例;<12月龄儿童报告55例百日咳死亡。
  • 2014-2016年期间未报告百日咳死亡。
  • <12月龄婴儿发病率从209.4/10万(2005-2012)降至49.1/10万(2014-2016),下降87.5%(95%CI 77.2-93.2%)。
  • ≤6周龄婴儿发病率从196.7/10万降至89.6/10万(下降54.4%,95%CI 35.4-67.9%);7-<28周下降73.4%(95%CI 68.4-77.6%);28-52周下降100%。
  • 孕妇疫苗覆盖率从2013-2015年的<60%上升至2016年的80%。

临床怎么用

  • 可将孕妇Tdap接种作为降低小月龄婴儿百日咳发病与死亡的综合防控措施之一。
  • 应关注≤6周龄婴儿发病率降幅相对较小,持续监测并提高孕妇疫苗覆盖率。

局限性

  • 研究为观察性监测数据分析,孕妇免疫实施与发病率下降之间的因果关联不能确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal immunization with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine confers protection to young infants. We aimed to describe trends in pertussis incidence and associated mortality in children aged <12 months before and after introduction of maternal Tdap immunization in Bogotá, Colombia. METHODS: Data on pertussis-related cases/deaths in infants aged <12 months were collected from SIVIGILA for the period 2005-2016, and compared incidence for the pre-vaccine introduction (2005-2012) and post-maternal Tdap vaccination (2014-2016) periods in infants aged <12 months and in three distinct age-strata; ≤6 weeks, 7-<28 weeks, and 28-52 weeks. Mortality comparisons were performed in all infants <12 months. RESULTS: From 2005 to 2016, 2315 laboratory or clinically-confirmed pertussis cases were reported in infants <12 months of age (278 cases in young infants aged ≤6 weeks); 55 pertussis deaths were reported in children aged <12 months. No pertussis deaths were reported in the 2014-2016 period. Since maternal Tdap introduction in 2013, a consistent decline in pertussis incidence and mortality was observed. In the time-series analysis, incidence declined from 209.4/100,000 persons (2005-2012) to 49.1/100,000 persons (2014-2016) in all children <12 months; a 87.5% (95%CI: 77.2-93.2%) reduction. For these same period's incidence in young infants ≤6 weeks declined from 196.7 to 89.6/100,000 person-years (an 54.4% [95% CI: 35.4-67.9%] reduction). Greater incidence reductions were observed in older infants; 73.4% (95% CI: 68.4-77.6%) in those aged 7-<28 weeks, and 100% in those aged 28-52 weeks. A 100% reduction in Pertussis mortality in infants <12 months was observed. Since Tdap introduction, maternal vaccine coverage rose from <60% in 2013-2015 to 80% in 2016. CONCLUSIONS: Implementation of maternal immunization in Bogotá may have contributed to the reduction in pertussis incidence and mortality among infants <12 months of age (ClinicalTrials.gov: NCT02569879). An Audio Summary linked to this article that can be found on Figshare https://doi.org/10.6084/m9.figshare.12943316.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Carrasquilla G, Porras A, Martinez S, et al. Incidence and mortality of pertussis disease in infants <12 months of age following introduction of pertussis maternal universal mass vaccination in Bogotá, Colombia. Vaccine. 2020. PMID: 33012607. doi:10.1016/j.vaccine.2020.07.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。